Nanocarriers for delivery of antioxidants to endothelium
用于将抗氧化剂递送至内皮的纳米载体
基本信息
- 批准号:6816060
- 负责人:
- 金额:$ 39.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-08-11 至 2008-04-30
- 项目状态:已结题
- 来源:
- 关键词:acidity /alkalinityantioxidantsbinding sitesbioengineering /biomedical engineeringbiotechnologycatalasechemical structure functiondisease /disorder modeldrug administration rate /durationdrug design /synthesis /productiondrug metabolismdrug screening /evaluationdrug vehiclehydrogen peroxideintermolecular interactionintracellular transportlaboratory mouselaboratory ratlung ischemia /hypoxiananomedicinenonhuman therapy evaluationoxidative stresspolymersprotein localizationprotein metabolismproteolysisrespiratory disorder chemotherapyvascular endothelium
项目摘要
DESCRIPTION (provided by applicant):
Vascular oxidant stress plays a key role in many pathologic states including hyperoxia, inflammation, ischemia, pulmonary and cardiovascular diseases. However, current antioxidant therapies are not effective, in part due to sub-optimal delivery to endothelial cells (EC). Previous studies have shown that the antioxidant enzyme (AOE) catalase (that detoxifies freely diffusing H2O2) conjugated with antibodies to endothelial Cell Adhesion Molecules (CAM) accumulates in EC after intravenous injection and protects animals against acute oxidant lung injury. Unfortunately, anti-CAM/AOE conjugates are eliminated from the blood and degraded in the EC within a few hours, affording only transient effects. In order to solve this problem and to achieve higher therapeutic duration and utility, we propose to load catalase into H2O2-permeable, anti-CAM targeted di-block PEG-PLGA Polymer Nano-Carriers (PNC) that would prolong the AOE circulation and protect from lysosomal proteolysis. Pilot data show that catalase loaded inside stealth anti-CAM/PNC degrades H2O2, binds to and protects EC from oxidant injury, circulates in animals for a prolonged time, and accumulates in the lung vasculature. The goal of this grant is to explore, test and optimize this strategy, pursuing the following Specific Aims: 1. Optimize the design of PNC for AOE delivery to EC. PEG-PLA PNC formulation, composition, size, AOE loading, activity and protease resistance, rate of pH-dependent degradation, coupling of anti-CAM, binding, uptake and metabolism by EC, and protection of EC will be studied and optimized in vitro. 2. Characterize the behavior and targeting of anti-CAM/PNC/AOE in vivo. Their blood clearance, systemic effects, biodistribution, EC binding, pulmonary targeting, optimal administration routes and persistence in lungs will be tested in naive animals and animals with oxidant vascular stress. 3. Evaluate the effects of anti-CAM/PNC/AOE in animals. Mouse models of acute H2O2 generation in the pulmonary vasculature and sub-acute oxidant stress in the lungs (hyperoxia) will be employed to evaluate the degree and duration of protection, and refine regimens of AOE targeting and mechanisms of protection. Completion of these Aims will be a major step towards the long-term goal of our research, which is translation of this promising new technology platform into the clinical domain.
描述(由申请人提供):
血管氧化应激在许多病理状态中起关键作用,包括高氧、炎症、缺血、肺和心血管疾病。然而,目前的抗氧化剂疗法并不有效,部分原因是对内皮细胞(EC)的输送不够理想。先前的研究表明,抗氧化酶(AOE)过氧化氢酶(能解毒,能自由扩散的过氧化氢)与抗内皮细胞黏附分子(CAM)抗体结合后,在静脉注射后聚集在EC中,保护动物免受急性氧化性肺损伤。不幸的是,抗CAM/AOE结合物在几个小时内从血液中清除并在EC中降解,仅提供短暂的效果。为了解决这一问题,并获得更高的治疗时间和实用性,我们建议将过氧化氢酶负载到过氧化氢透过性的、抗CAM靶向的双嵌段聚乙二醇聚乳酸聚合物纳米载体(PNC)中,以延长AOE循环并防止溶酶体蛋白降解。中试数据显示,装载在隐形抗CAM/PNC中的过氧化氢酶降解过氧化氢,结合并保护EC免受氧化损伤,在动物体内循环较长时间,并在肺血管系统中积累。这笔赠款的目标是探索、测试和优化这一战略,追求以下具体目标:1.优化面向EC的AOE交付的PNC设计。聚乙二醇聚乳酸PNC的处方、组成、大小、AOE负载量、活性和对蛋白酶的抗性、pH依赖的降解率、抗CAM的偶联、EC的结合、摄取和代谢以及EC的保护等方面将在体外进行研究和优化。2.研究抗CAM/PNC/AOE抗体在体内的行为和靶向性。它们的血液清除、全身效应、生物分布、EC结合、肺靶向、最佳给药途径和肺内持久性将在幼稚动物和氧化血管应激动物身上进行测试。3.评价抗CAM/PNC/AOE的动物实验效果。将采用小鼠肺血管产生急性过氧化氢和肺内亚急性氧化应激(高氧)的模型来评估保护的程度和持续时间,并改进AOE的靶向方案和保护机制。完成这些目标将是朝着我们研究的长期目标迈出的重要一步,也就是将这一前景看好的新技术平台转化为临床领域。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)
Targeted endothelial delivery of nanosized catalase immunoconjugates protects lung grafts donated after cardiac death.
- DOI:10.1097/tp.0b013e318226bc6b
- 发表时间:2011-08-27
- 期刊:
- 影响因子:6.2
- 作者:Preissler G;Loehe F;Huff IV;Ebersberger U;Shuvaev VV;Bittmann I;Hermanns I;Kirkpatrick JC;Fischer K;Eichhorn ME;Winter H;Jauch KW;Albelda SM;Muzykantov VR;Wiewrodt R
- 通讯作者:Wiewrodt R
Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates.
根据抗体 - 抗氧化剂酶结合的大小对内皮靶向的调节。
- DOI:10.1016/j.jconrel.2010.10.026
- 发表时间:2011-02-10
- 期刊:
- 影响因子:0
- 作者:Shuvaev VV;Tliba S;Pick J;Arguiri E;Christofidou-Solomidou M;Albelda SM;Muzykantov VR
- 通讯作者:Muzykantov VR
NO gets a test ride on high-tech transporting nanodevices: A commentary on "Sustained-release nitric oxide from long-lived circulating nanoparticles".
- DOI:10.1016/j.freeradbiomed.2010.05.022
- 发表时间:2010-08
- 期刊:
- 影响因子:7.4
- 作者:V. Muzykantov
- 通讯作者:V. Muzykantov
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Vladimir R Muzykantov其他文献
Vladimir R Muzykantov的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Vladimir R Muzykantov', 18)}}的其他基金
Dual drug delivery to lung/blood interface in respiratory infections.
在呼吸道感染中向肺/血液界面双重给药。
- 批准号:
10179690 - 财政年份:2021
- 资助金额:
$ 39.63万 - 项目类别:
Dual drug delivery to lung/blood interface in respiratory infections.
在呼吸道感染中向肺/血液界面双重给药。
- 批准号:
10614476 - 财政年份:2021
- 资助金额:
$ 39.63万 - 项目类别:
Dual drug delivery to lung/blood interface in respiratory infections.
在呼吸道感染中向肺/血液界面双重给药。
- 批准号:
10393610 - 财政年份:2021
- 资助金额:
$ 39.63万 - 项目类别:
Vascular delivery of nanocarriers by erythrocyres
红细胞对纳米载体的血管输送
- 批准号:
9922385 - 财政年份:2018
- 资助金额:
$ 39.63万 - 项目类别:
相似海外基金
Enhancing gamete cryoprotective properties of graphene oxide by dual functionalization with antioxidants and non-penetrating cryoprotectant molecules
通过抗氧化剂和非渗透性冷冻保护剂分子的双重功能化增强氧化石墨烯的配子冷冻保护特性
- 批准号:
24K18002 - 财政年份:2024
- 资助金额:
$ 39.63万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Bilirubin Catabolism induces Plasminogen-Activator Inhibitor 1 (PAI-1) worsening Metabolic Dysfunction
胆红素分解代谢诱导纤溶酶原激活剂抑制剂 1 (PAI-1) 恶化代谢功能障碍
- 批准号:
10750132 - 财政年份:2024
- 资助金额:
$ 39.63万 - 项目类别:
Biology the initiator: Harnessing Reactive Oxygen Species for Biocompatible Polymerization
生物学引发者:利用活性氧进行生物相容性聚合
- 批准号:
10667740 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Developing Tools to Understand an Alternative Fate of Urate in Neurodegenerative Diseases
开发工具来了解尿酸盐在神经退行性疾病中的替代命运
- 批准号:
10668103 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Heat therapy for the treatment of SCI-induced changes in nociceptor and mitochondrial function
热疗法治疗 SCI 引起的伤害感受器和线粒体功能变化
- 批准号:
10641385 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Exploring regulatory mechanisms of glyoxalase-1
探索乙二醛酶-1的调控机制
- 批准号:
10646721 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Oxidative Stress and Mitochondrial Dysfunction in Chemogenetic Heart Failure
化学遗传性心力衰竭中的氧化应激和线粒体功能障碍
- 批准号:
10643012 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Combinatorial Neuroprotective Strategies for Preterm Brain Injury
早产儿脑损伤的组合神经保护策略
- 批准号:
10798705 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:














{{item.name}}会员




